Storys zum Thema Health

Folgen
Keine Story zum Thema Health mehr verpassen.
Filtern
  • 09.05.2006 – 08:04

    Gemplus

    Gemplus Wins Contract for 3.7 Million Secure Healthcare Cards in Mexico

    Luxembourg and Mexico City (ots/PRNewswire) - - Gemplus Delivers Healthcare ID Card, Software and Services to Mexico's Seguro Popular for Patient Data Storage Gemplus International S.A. (Euronext: LU0121706294 - GEM and NASDAQ: GEMP), a world leading provider of secure card solutions announces the delivery of 3.7 million smart healthcare cards to Seguro ...

  • 04.05.2006 – 10:04

    Fendi Presse

    Fendi and Sharon Stone to Benefit amfAR

    Paris (ots/PRNewswire) - Fendi and Sharon Stone have joined forces for the amfAR - American Foundation for AIDS Research. (Photo: http://www.newscom.com/cgi-bin/prnh/20060504/211357-a ) (Photo: http://www.newscom.com/cgi-bin/prnh/20060504/211357-b ) Sharon Stone, in collaboration with Fendi, has created a luxury travel set that she will auction off, with all profits to be presented to amfAR at the 'Cinema ...

  • 27.04.2006 – 09:24

    Zeltia Group

    Zeltia Increases R&D Investment by 32.2% in the First Quarter 2006

    Madrid (ots/PRNewswire) - - Revenue Amounted to 14.8 Million Euros - Marketing Expenditure Increased 52.1% to 5.1 Million Euros - The Group Invested 11.8 Million Euros in Research and Development, Up 32% Zeltia S.A. (ZEL SM; ZEL MC) today presented its financial results for the first quarter of 2006, which showed a significant increase in Research & Development (R&D) spend, to 11.8 million euros. ...

  • 25.04.2006 – 15:21

    Isotechnika Inc.

    Isotechnika Signs Option Agreement for Topical Delivery Technology of ISA247

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has signed an option agreement with Cellgate Inc. of Redwood City, California. This agreement allows Isotechnika the option to obtain an exclusive license to develop and commercialize conjugates consisting of Cellgate's patented transporter technology for the topical delivery of ...

  • 21.04.2006 – 19:15

    Boston Scientific

    Boston Scientific Completes Combination With Guidant

    Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today announced that it has completed its combination with Guidant Corporation (NYSE: GDT), creating a global leader in cardiovascular devices and one of the largest medical technology companies in the world. In a related transaction before the closing of the Boston Scientific-Guidant transaction, Guidant and Abbott closed ...

  • 13.04.2006 – 12:04

    World Federation of Hemophilia

    Global Hemophilia Community Campaigns to Stop Childhood Deaths

    Montreal, Canada (ots/PRNewswire) - "No child born with a bleeding disorder should have to live with pain, disability, or the prospect of early death," says Mark Skinner, president of the World Federation of Hemophilia (WFH). He was speaking on the eve of World Hemophilia Day, (April 17) which has adopted the message this year of Treatment for all! "With treatment, a person with hemophilia can expect to live ...

  • 07.04.2006 – 14:30

    Ferring International SA

    Degarelix, a novel GnRH Blocker from Ferring, moves into phase III

    21st Annual Meeting of the European Association of Urology (EAU), Paris, 5th - 8th April 2006 Treatment with degarelix results in fast, profound and sustained reductions in testosterone and prostate-specific antigen (PSA) levels without a testosterone surge Paris (ots) - Following the presentation today of the results of the Phase IIb programme with degarelix in prostate cancer, which are in line with previous ...

  • 04.04.2006 – 08:35

    Zeltia S.A.

    PharmaMar Highlights Aplidin(R) Results at AACR

    Washington D.c. (ots/PRNewswire) - PharmaMar today announces the presentation of five posters highlighting advances with three of its compounds at the 97th Annual Meeting of the American Association for Cancer Research (AACR), taking place in Washington from 1-5 April 2006. The posters include results from preclinical research on Aplidin(R), Zalypsis(R) and PM02734. PharmaMar's highlights from this year's AACR ...